MicroRNA-599 targets high-mobility group AT-hook 2 to inhibit cell proliferation and invasion in clear cell renal carcinoma Retraction in /10.3892/mmr.2023.13041

Zhao,Hailing; Zhao,Huizhen; Xia,Xiaolin; Liu,Xiujuan

doi:10.3892/mmr.2018.8755

MicroRNA-599 targets high-mobility group AT-hook 2 to inhibit cell proliferation and invasion in clear cell renal carcinoma

Retraction in: /10.3892/mmr.2023.13041

Authors:
- Hailing Zhao
- Huizhen Zhao
- Xiaolin Xia
- Xiujuan Liu
View Affiliations

Affiliations: Department of Pediatrics, Yidu Central Hospital of Weifang, Weifang, Shandong 262550, P.R. China, Department of Nephrology, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
Published online on: March 15, 2018 https://doi.org/10.3892/mmr.2018.8755
Pages: 7451-7459

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dysregulation of microRNAs (miRNAs) is associated with the occurrence and development of clear cell renal cell carcinoma (ccRCC) through their participation in a number of critical biological processes. Therefore, an in‑depth investigation into miRNAs and their biological roles within ccRCC may provide useful insights and lead to the identification of novel therapeutic methods for patients with ccRCC. miRNA‑599 (miR‑599) serves critical roles in different types of human cancer. However, the expression pattern, biological function and molecular mechanism of miR‑599 in ccRCC remain unknown. The present study aimed to detect the expression level of miR‑599 in ccRCC, examine its effect on ccRCC progression and further explore the possible underlying mechanisms. It was observed that miR‑599 was significantly underexpressed in ccRCC tissues and cell lines compared with the control. Functional assays revealed that restored expression of miR‑599 restricted the proliferation and invasion of ccRCC cells. Bioinformatics analysis, luciferase reporter assay, reverse transcription‑quantitative polymerase chain reaction and western blot analysis demonstrated that high‑mobility group AT‑hook 2 (HMGA2) was a direct target of miR‑599 in ccRCC. HMGA2 knockdown simulated the suppressive effects caused by miR‑599 overexpression in ccRCC. Recovered HMGA2 expression partially rescued the miR‑599‑mediated inhibition of ccRCC proliferation and invasion. These results suggest that miR‑599 may serve tumour suppressive roles in ccRCC by directly targeting HMGA2, indicating that miR‑599 may have potential as a treatment for patients with ccRCC.

View Figures

View References

1	Rasmussen F: Metastatic renal cell cancer. Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Cheville JC, Lohse CM, Zincke H, Weaver AL and Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 27:612–624. 2003. View Article : Google Scholar : PubMed/NCBI
4	Chen Z, Zhang J, Zhang Z, Feng Z, Wei J, Lu J, Fang Y, Liang Y, Cen J, Pan Y, et al: The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis. 8:e28592017. View Article : Google Scholar : PubMed/NCBI
5	Chow WH and Devesa SS: Contemporary epidemiology of renal cell cancer. Cancer J. 14:288–301. 2008. View Article : Google Scholar : PubMed/NCBI
6	Hadoux J, Vignot S and De La Motte Rouge T: Renal cell carcinoma: Focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar : PubMed/NCBI
7	Liu TY, Li J, Wen XH, Zhang H and Gui Q: The efficacy of open nephron-sparing surgery in the treatment of complex renal cell carcinoma. Eur Rev Med Pharmacol Sci. 20:3959–3964. 2016.PubMed/NCBI
8	Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lui PY, Jin DY and Stevenson NJ: MicroRNA: Master controllers of intracellular signaling pathways. Cell Mol Life Sci. 72:3531–3542. 2015. View Article : Google Scholar : PubMed/NCBI
10	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
11	Jonas S and Izaurralde E: Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 16:421–433. 2015. View Article : Google Scholar : PubMed/NCBI
12	Giannakakis A, Coukos G, Hatzigeorgiou A, Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wang R, Ma Y, Yu D, Zhao J and Ma P: miR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1. Biomed Pharmacother. 70:64–71. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lei Z, Ma X, Li H, Zhang Y, Gao Y, Fan Y, Li X, Chen L, Xie Y, Chen J, et al: Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis. Urol Oncol. Oct 20–2017.(Epub ahead of print). PubMed/NCBI
15	Cao J, Liu J, Xu R, Zhu X, Liu L and Zhao X: MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. Mol Med Rep. 13:75–82. 2016. View Article : Google Scholar : PubMed/NCBI
16	Nakata W, Uemura M, Sato M, Fujita K, Jingushi K, Ueda Y, Kitae K, Tsujikawa K and Nonomura N: Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma. Oncotarget. 6:21645–21654. 2015. View Article : Google Scholar : PubMed/NCBI
17	Xiao H, Zeng J, Li H, Chen K, Yu G, Hu J, Tang K, Zhou H, Huang Q, Li A, Li Y, et al: MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget. 6:13201–13215. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Sui Y, Zhu Q and Sui X: Hsa-miR-599 suppresses the migration and invasion by targeting BRD4 in breast cancer. Oncol Lett. 14:3455–3462. 2017. View Article : Google Scholar : PubMed/NCBI
19	Tian J, Hu X, Gao W, Zhang J, Chen M, Zhang X, Ma J and Yuan H: Identification a novel tumor-suppressive hsa-miR-599 regulates cells proliferation, migration and invasion by targeting oncogenic MYC in hepatocellular carcinoma. Am J Transl Res. 8:2575–2584. 2016.PubMed/NCBI
20	Zhang T, Ma G, Zhang Y, Huo H and Zhao Y: miR-599 inhibits proliferation and invasion of glioma by targeting periostin. Biotechnol Lett. 39:1325–1333. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wang D, Zhu C, Zhang Y, Zheng Y, Ma F, Su L and Shao G: MicroRNA-30e-3p inhibits cell invasion and migration in clear cell renal cell carcinoma by targeting Snail1. Oncol Lett. 13:2053–2058. 2017. View Article : Google Scholar : PubMed/NCBI
22	Fan W, Huang J, Xiao H and Liang Z: MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN. Mol Med Rep. 13:4800–4806. 2016. View Article : Google Scholar : PubMed/NCBI
23	Ma X, Shen D, Li H, Zhang Y, Lv X, Huang Q, Gao Y, Li X, Gu L, Xiu S, et al: MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urol Oncol. 33:169.e1–11. 2015. View Article : Google Scholar
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Liu Y, Fu QZ, Pu L, Meng QG, Liu XF, Dong SF, Yang JX and Lv GY: HMGA2 expression in renal carcinoma and its clinical significance. J Med Biochem. 34:338–343. 2015. View Article : Google Scholar : PubMed/NCBI
26	Na N, Si T, Huang Z, Miao B, Hong L, Li H and Qiu J and Qiu J: High expression of HMGA2 predicts poor survival in patients with clear cell renal cell carcinoma. Onco Targets Ther. 9:7199–7205. 2016. View Article : Google Scholar : PubMed/NCBI
27	Liu Y, Fu QZ, Pu L, Song LL, Wang YY, Liu J, Wang ZL and Wang ZM: Effect of RNA interference of the expression of HMGA2 on the proliferation and invasion ability of ACHN renal cell carcinoma cells. Mol Med Rep. 16:5107–5112. 2017. View Article : Google Scholar : PubMed/NCBI
28	Kou B, Liu W, Tang X and Kou Q: HMGA2 facilitates epithelial-mesenchymal transition in renal cell carcinoma by regulating the TGF-β/Smad2 signaling pathway. Oncol Rep. 39:101–108. 2018.PubMed/NCBI
29	Liu LJ, Yu JJ and Xu XL: MicroRNA-93 inhibits apoptosis and promotes proliferation, invasion and migration of renal cell carcinoma ACHN cells via the TGF-β/Smad signaling pathway by targeting RUNX3. Am J Transl Res. 9:3499–3513. 2017.PubMed/NCBI
30	He YH, Chen C and Shi Z: The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma. J Cell Physiol. Dec 7–2017.(Epub ahead of print).
31	Xiao W, Lou N, Ruan H, Bao L, Xiong Z, Yuan C, Tong J, Xu G, Zhou Y, Qu Y, et al: Mir-144-3p promotes cell proliferation, metastasis, sunitinib resistance in clear cell renal cell carcinoma by downregulating ARID1A. Cell Physiol Biochem. 43:2420–2433. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wang X, Jin Y, Zhang H, Huang X, Zhang Y and Zhu J: MicroRNA-599 inhibits metastasis and epithelial-mesenchymal transition via targeting EIF5A2 in gastric cancer. Biomed Pharmacother. 97:473–480. 2018. View Article : Google Scholar : PubMed/NCBI
33	Tian W, Wang G, Liu Y, Huang Z, Zhang C, Ning K, Yu C, Shen Y, Wang M, Li Y, et al: The miR-599 promotes non-small cell lung cancer cell invasion via SATB2. Biochem Biophys Res Commun. 485:35–40. 2017. View Article : Google Scholar : PubMed/NCBI
34	Sun M, Song CX, Huang H, Frankenberger CA, Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C and Rosner MR: HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA. 110:pp. 9920–9925. 2013; View Article : Google Scholar : PubMed/NCBI
35	Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S and Bullerdiek J: Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer. 47:56–63. 2008. View Article : Google Scholar : PubMed/NCBI
36	Esmailzadeh S, Mansoori B, Mohammadi A, Shanehbandi D and Baradaran B: siRNA-mediated silencing of HMGA2 induces apoptosis and cell cycle arrest in human colorectal carcinoma. J Gastrointest Cancer. 48:156–163. 2017. View Article : Google Scholar : PubMed/NCBI
37	Kaur H, Ali SZ, Huey L, Hütt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG and Raabe EH: The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 377:55–64. 2016. View Article : Google Scholar :